Didox
Alternative Names: N,3,4-trihydroxybenzamide (Didox); NSC 324360; VF 14Latest Information Update: 28 Sep 2024
At a glance
- Originator Molecules for Health
- Class Antianaemics; Antineoplastics; Antipsoriatics; Antiretrovirals; Antivirals; Benzamides; Hydroxamic acids; Small molecules
- Mechanism of Action Ribonucleoside diphosphate reductase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Breast cancer
- No development reported Cytomegalovirus infections; HIV infections; Psoriasis; Sickle cell anaemia
Most Recent Events
- 28 Sep 2024 No recent reports of development identified for preclinical development in Sickle-cell-anaemia in USA
- 26 Sep 2022 Clinical development for Breast cancer is ongoing (Molecules for Health website, September 2022)
- 10 Apr 2021 Pharmacodynamics data from preclinical studies in Breast cancer presented at the 112th Annual Meeting of the American Association for Cancer Research (AACR-2021)